1. Search Result
Search Result
Results for "

hemorrhagic lesion

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162596

    BA-1049 free base

    ROCK Neurological Disease
    NRL-1049 (BA-1049 (free base)) is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .
    NRL-1049
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B
  • HY-N6726

    Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3
  • HY-N6726S

    Isotope-Labeled Compounds Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3- 13C34 is the 13C labeled Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3-13C34
  • HY-120381

    CAM 1189

    Cholecystokinin Receptor Neurological Disease Inflammation/Immunology
    PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats .
    PD 136450
  • HY-167824

    Endogenous Metabolite Neurological Disease
    SSR180711 is a potent and subtype-selective α7 agonist with activity in Alzheimer's disease and schizophrenia research. SSR180711 can be used to study subtypes of intracerebral hemorrhage associated with cerebral small vessel disease. SSR180711 shows potential in electrophysiological and behavioral studies to evaluate its effects on cognitive function. SSR180711 also has potential for studying cerebrovascular lesions and their effects .
    SSR180711
  • HY-N6726R

    Reference Standards Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3 (Standard) is the analytical standard of Fumonisin B3. This product is intended for research and analytical applications. Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3 (Standard)
  • HY-N6726S1

    Isotope-Labeled Compounds Fungal Endogenous Metabolite Infection Cancer
    Fumonisin B3-13C34-1 is the isotopic internal standard of Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
    Fumonisin B3-13C34-1
  • HY-162596A

    (Rac)-BA-1049

    ROCK Neurological Disease
    (Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .
    (Rac)-NRL-1049 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: